Diffuse large B-cell lymphoma-treatment approaches in the molecular era. (Q38161760)

30 August 2017

Diffuse large B-cell lymphoma-treatment approaches in the molecular era. (English)

1 reference

30 August 2017

3

Wyndham H Wilson

1 reference

30 August 2017

Mark Roschewski

1

1 reference

PubMed ID

24217204

30 August 2017

Louis M Staudt

series ordinal

2

1 reference

PubMed ID

24217204

30 August 2017

language of work or name

English

0 references

publication date

12 November 2013

1 reference

Nature Reviews Clinical Oncology

30 August 2017

1 reference

30 August 2017

11

1 reference

30 August 2017

1

1 reference

30 August 2017

12-23

1 reference

30 August 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

My treatment approach to patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Relapsed/refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Advanced diffuse histiocytic lymphoma, a potentially curable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Analysis of the coding genome of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Genetic heterogeneity of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Double-hit B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Development of PI3K inhibitors: lessons learned from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

BCL2 mutations in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Integration of B cell responses through Toll-like receptors and antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Malignant pirates of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Oncogenically active MYD88 mutations in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Frequent inactivation of A20 in B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Prostate stem cell antigen is overexpressed in prostate cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Lenalidomide - current understanding of mechanistic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

B cell antigen receptor signaling 101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

PI3 kinase signals BCR-dependent mature B cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

B cell antigen receptor signaling: roles in cell development and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Targeting pathological B cell receptor signalling in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

MALT1 protease: a new therapeutic target in B lymphoma and beyond?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A new "brew" of MALT1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The human thymus contains a novel population of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The molecular pathogenesis of primary mediastinal large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Cooperative epigenetic modulation by cancer amplicon genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

PAK1 mediates resistance to PI3K inhibition in lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Pathogenesis of human B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.197

Deletions in the long arm of chromosome 10 in lymphomas with t(14;18): a pathogenetic role of the tumor supressor genes PTEN/MMAC1 and MXI1?

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24217204

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24217204

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24217204

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2013.197

1 reference

30 August 2017

0 references

1 reference

PubMed ID

24217204